Janssen Research & Development, LLC
Phase 3 Estimated
Seltorexant
Depressive Disorder, Major
Countdown
176days
Phase 3 readout · Dec 30, 2026
What's at stake Phase 3 trial results for Seltorexant in Depressive Disorder, Major are due Dec 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
“CT.gov NCT06559306: Phase 3 trial, sponsor Janssen Research & Development, LLC, drug Seltorexant. Primary completion date 2026-12-30 (estimated).”

Provenance

1 source on file. Trial NCT06559306.

Link copied ✓